Home » Newsletters » BioWorld Science

BioWorld Science

April 11, 2012

View Archived Issues

Preclinical and first clinical data disclosed on MLN-2480

Bayer Healthcare presents new oral selective PI3K inhibitor

Research at Astellas yields novel phosphodiesterase 9A inhibitors

UCB describes new PI3K inhibitors

Novel histone deacetylase inhibitors patented by Roche

IRM discloses new Trk inhibitors

Novel potential malaria therapies discovered

New HCV NS3/NS4A inhibitor characterized

Takeda reports on efforts to develop new HER2/EGFR kinase inhibitors

Mutant caveolin-1-derived peptide reduces atherosclerotic lesions

Novel ApoA-I-mimetic peptide shows promise as atherosclerosis drug

Affymax receives new milestone payment from Takeda for Omontys

AmiKet receives FDA fast track status

Phase II AKB-6548 study meets primary endpoint

Omeros begins enrollment in second phase III OMS-302 trial

Marshall Edwards clear to move lead mitochondrial inhibitor to clinic

PharmaMar to halt Irvalec development in gastroesophageal tumors

KineMed receives NIH grant to support development of ApoA-I HDL mimetic

Korlym now available in U.S.

Targacept reports revised topline data from phase II TC-6987 study

AnaptysBio enters strategic antibody discovery partnership

Sucampo reports topline phase III lubiprostone data

HSP 90 inhibitor enters phase I trial in multiple myeloma

Stealth Peptides reports on phase I Bendavia studies

Biovest to file marketing application in Canada

Amgen announces new acquisition agreement

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 3, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...